• Led and coached a team of junior scientists to support company goals.• Led the design, execution, and interpretation of on- and off-chip experimental workflows.• Managed projects by securing necessary resources.• Communicated and reported study findings, and future direction to internal and external audiences while maintaining up-to-date scientific and technical knowledge.• Drove the strategy and development of new Organ-Chip models with immune cells.• Developed a human-relevant model using Colon Intestine-Chip to simulate immune cell recruitment, reproduce inflammatory response and validate targeted therapeutics.• Participated in customer calls and engaged in scientific discussions. • Contributed extensively through multiple scientific presentations, manuscript publications, and reports to internal and external audiences.• Designed and performed fee-for-service studies across multiple organ models. • Contributed to improved customer experience by collaborating with business development executives.

• Led multiple external projects with pharmaceutical companies delivering successful data that led to re-occurring clients/contracts. • Managed 2-direct reports and collaborated effectively with other internal teams to produce desired results and exceed timeline expectations. • Surpassed targeted team’s total revenue goal and created new opportunities for revenue growth. • Designed and executed studies on multiple organ-chip models, including Caco-2 Intestine-Chip, Duodenum Intestine-Chip, Colon Intestine-Chip, and alveolar Lung-Chip. • Evaluated the effect of a Probiotic control and proprietary bacterial strains on low-grade inflammation in the Duodenum Intestine-Chip and tested novel cancer immunotherapy molecules for safety and efficacy with different donors in the Colon Intestine-Chip.

• Designed and executed studies to identify molecular strategies that increase sensitivity of murine cells to Shiga toxins from Enterohemorrhagic E. coli in preparation for a mouse model. The hypothesis is that increased toxin receptors on murine endothelial cells will confer toxin sensitivity and coagulopathy in an otherwise resistant species. Identification of effective strategies will be applied in a murine model to study molecular pathogenesis and therapeutic opportunities• Developed diverse assays to examine the Shiga-toxin receptor Gb3 in murine endothelial cells, including: endoplasmic reticulum (ER) stress and apoptosis biomarkers to identify toxin sensitive cells by qPCR, flow cytometry to quantify Gb3 glycolipid expression after siRNA manipulation of biosynthetic alpha-galactosidase A and B4GALNT2 pathways• Identified efficacious siRNAs for multiple target genes for in vitro studies• Initiated murine coagulation assay portfolio for laboratory. This included plasma clotting time, fibrinogen concentration, and D-dimer level by coagulometer and ELISA• Laboratory Manager responsible for daily and long-term organization and function of the laboratory • Mentored graduate and summer students (PhD, Master’s, under-represented minority undergraduate students) with limited skill sets• Excellent project management, problem-solving, data organization and written and oral communication skills for presentation, progress reports, and publications

• Conducted experiments to achieve gastric cell death by activating N-methyl D- aspartate (NMDA) channel, which results in Ca2+ permeation and depolarization of the mitochondrial transmembrane potential• Identified NMDA receptor is an important role for Ca2+ permeation and in gastric apoptosis• Designed and directed experiments using multiple lab biochemical techniques such as western blot, ELISA, immunohistochemistry, Live cell imaging, confocal microscopy• Determined histotechnology-based assays on cells and tissues include harvesting, fixing, processing, staining and coverslipping and perform immunohistochemistry• In vitro and ex-vivo experiment including isolated primary gastric parietal and chief cells from rat. Grew and maintained a wide range of cancer cell lines, performed cellular proliferation, apoptosis, signaling and viability assays• Collaborated with Dr. James Fox in the Department of Biological Engineering at the Massachusetts Institute of Technology

• Investigated signal transduction pathways involved in the redox regulation of H. pylori -infected gastric epithelial cells by using molecular biology approaches such as RT-PCR, Western blot, ELISA, and EMSA• Examined the effects of antioxidants on a H. pylori-infected cellular model of gastric inflammation via cytokine profiling (ELISA), transcription factor activation(EMSA), and gene expression at the transcription level (luciferase assay)• Selected for oral presentations from numerous conferences; Experimental Biology 2012, World Congress of Cellular and Molecular Biology 2005, International Congress on Amino Acids and Proteins 2005, . IUPHAR GI Symposium "Advances in GI Pharmacology 2004, Asian Congress of Nutrition 2003

Facilitated medical students to current advances in pharmacological research and drug developmentTaught medical students in basic pharmacology as applied in a clinical context

Examined bone marrow stromal cells (BMSCs) as an attractive target forgenetic modification in the treatment of malignant diseases.